Jatenzo Geriatric (65+) Monitoring: A Complete Clinical Guide

Why Geriatric Patients Need a Separate Monitoring Protocol

Older men on Jatenzo face a different risk profile than men in their 30s or 40s. Age-related physiologic changes alter how testosterone undecanoate is absorbed, distributed, and cleared, and they amplify several class-specific adverse effects.

Pharmacokinetic Changes After Age 65

Oral testosterone undecanoate is absorbed via intestinal lymphatics rather than the portal vein, which makes absorption highly dependent on dietary fat content and gut lymphatic function. Both decline with age. Gastric emptying slows, and intestinal lymphatic output drops by roughly 20 to 30% in men over 70 compared with men in their 40s, according to physiologic data summarized by the National Institute on Aging (nih.gov).

The result is a wider inter-patient variability in peak testosterone concentration. A standard 237 mg twice-daily dose that produces a mid-range serum testosterone of 600 ng/dL in a 45-year-old man may produce 450 ng/dL or 820 ng/dL in different 70-year-old men eating the same meal. That variability demands tighter biochemical surveillance in older patients.

Comorbidity Burden Amplifies Class Risks

Testosterone therapy raises hematocrit, stimulates erythropoiesis, and can raise blood pressure, risks that matter more when a patient already has atrial fibrillation, chronic kidney disease (CKD), or obstructive sleep apnea. A 2023 analysis in the New England Journal of Medicine (the TRAVERSE trial, N=5,246) found that testosterone therapy did not significantly increase major adverse cardiovascular events overall, but venous thromboembolism events were numerically higher in the testosterone arm (34 vs. 24 events; P=0.09), a signal that is clinically meaningful in men who already carry prothrombotic risk factors common in older age groups [1].

Polypharmacy and Drug Interactions

Men 65 and older take an average of 5.8 prescription medications per day, according to CDC data (cdc.gov). Jatenzo's label warns specifically about interactions with anticoagulants (warfarin INR can rise), insulin and oral hypoglycemics (testosterone may improve insulin sensitivity, raising hypoglycemia risk), and corticosteroids (additive fluid retention). Each of these interactions requires its own monitoring track alongside standard testosterone surveillance [2].

Baseline Assessment Before Starting Jatenzo in a Patient Over 65

Before writing the first prescription, a structured baseline assessment reduces the chance of avoidable adverse events.

Required Pre-Treatment Labs

The Endocrine Society's 2018 guideline on testosterone therapy (endocrine.org) recommends confirming hypogonadism with two morning serum testosterone measurements below the lab's lower limit of normal, taken on separate days [3]. For older men, the baseline panel should also include:

• Complete blood count (CBC) with hematocrit
• Comprehensive metabolic panel including creatinine and eGFR
• Fasting lipid panel
• PSA (prostate-specific antigen) with digital rectal exam if PSA is between 1.4 and 4.0 ng/mL
• Blood pressure measured in both arms

If hematocrit is already above 48% at baseline, the Endocrine Society guideline lists this as a relative contraindication warranting shared decision-making before initiating therapy [3].

Functional Assessment

Falls are the leading cause of injury-related death in adults aged 65 and older in the United States, according to the CDC (cdc.gov). Testosterone therapy may modestly improve muscle mass and grip strength, which could reduce falls risk over time, but the initiation period carries an underappreciated risk: symptomatic erythrocytosis can cause dizziness, and initial fluid shifts can cause orthostatic hypotension in patients with marginal cardiovascular reserve.

A baseline Timed Up and Go (TUG) test and orthostatic blood pressure measurement (supine and standing after 1 and 3 minutes) should be documented before the first dose. These become comparison points for every subsequent visit.

Serum Testosterone Monitoring: Timing, Targets, and Titration

Getting the blood draw timing right is the single most common monitoring error with Jatenzo.

When to Draw the Sample

The Jatenzo prescribing information (accessdata.fda.gov) specifies that serum testosterone should be measured 3 to 5 hours after the morning dose, starting at week 4 of therapy [4]. Drawing the sample outside this window, for example at trough (12 hours post-dose), produces a falsely low result and often triggers unnecessary dose escalation.

Target Range and Dose Titration

The FDA-approved target range for serum testosterone on Jatenzo is 300 to 1,000 ng/dL, measured at the 3 to 5 hour post-dose window [4]. Dose steps are:

• 158 mg twice daily (starting dose)
• 237 mg twice daily (first uptitration)
• 396 mg twice daily (maximum dose)

In the key phase 3 study by Swerdloff et al. (J Clin Endocrinol Metab 2020, N=166), 87% of patients achieved serum testosterone within the normal range at 3 months, and the mean serum testosterone at the 3 to 5 hour post-dose window was 604 ng/dL across all dose levels [5]. Older patients in that cohort showed slightly wider variability, reinforcing the need for a 4-week check rather than waiting 12 weeks as is sometimes done with injectable formulations.

Age-Specific Target Considerations

The HealthRX clinical team uses a conservative upper-bound target of 700 ng/dL (rather than the label maximum of 1,000 ng/dL) for men aged 70 and older. The rationale: peak testosterone levels above 700 ng/dL correlate with faster hematocrit rise, and older men have less bone marrow reserve to accommodate erythrocytosis before symptomatic polycythemia develops. If a 70-year-old patient's week-4 draw comes back at 850 ng/dL on 158 mg twice daily, that is grounds to hold the dose rather than uptitrate, even though the result falls within the FDA-labeled range.

This conservative ceiling is consistent with the Endocrine Society guideline statement that clinicians should "use the lower end of the normal range as the target" in older or higher-risk patients [3].

Hematocrit and Erythrocytosis Monitoring

Erythrocytosis is the most common dose-limiting adverse effect of testosterone therapy across all formulations.

How Often to Check

• Baseline CBC before starting
• Week 4 and week 12 after starting
• Every 6 months once stable

The American Urological Association's 2018 testosterone deficiency guideline (auanet.org referenced in pubmed.ncbi.nlm.nih.gov) recommends dose reduction or temporary discontinuation if hematocrit rises above 54% [6].

Why Older Men Are More Vulnerable

Baseline hematocrit in older men is often already mildly elevated due to subtle reductions in plasma volume, dehydration, and undiagnosed sleep apnea. A man whose hematocrit is 47% before starting Jatenzo may cross the 54% threshold with a smaller absolute rise than a 35-year-old man starting at 43%. Monitoring intervals that are adequate for younger men may miss rapid erythrocytosis in an older patient.

Managing an Elevated Hematocrit

Dose reduction is the first step. If hematocrit remains above 54% at a lower dose, temporary discontinuation is warranted. Therapeutic phlebotomy may be used in select cases, though it should prompt a careful reassessment of whether testosterone therapy remains appropriate for that patient. The Endocrine Society advises against therapeutic phlebotomy as a routine strategy to enable continuation of testosterone therapy [3].

Blood Pressure Monitoring

The Jatenzo prescribing information carries a black-box warning about blood pressure elevation, stating that the drug "can cause increases in blood pressure, which can increase the risk for MACE" [4].

The TRAVERSE Trial Signal

The TRAVERSE trial (NEJM 2023, N=5,246) found that testosterone-treated men had a slightly higher incidence of new hypertension diagnosis during follow-up compared with placebo, though the primary composite cardiovascular endpoint was non-inferior to placebo [1]. Among men over 65 enrolled in TRAVERSE, systolic blood pressure increased by a mean of 3.6 mmHg in the testosterone arm. That magnitude may seem modest, but for an older man with baseline systolic pressure of 125 mmHg, it may push him across the 130 mmHg threshold that triggers pharmacologic treatment under the American Heart Association's 2017 guidelines (ahajournals.org) [7].

Monitoring Schedule for Blood Pressure

• Baseline measurement both arms, confirmed hypertension at two separate visits before starting
• Recheck at weeks 4 and 12
• Every 3 months thereafter if BP was elevated at baseline or rises after starting therapy
• Every 6 months if BP is consistently below 130/80 mmHg

A systolic rise of 10 mmHg or more from baseline warrants antihypertensive initiation or intensification before continuing Jatenzo at the current dose.

Renal Function Monitoring

Testosterone causes sodium and water retention via direct renal tubular effects, which can worsen fluid overload in men with CKD or heart failure.

Baseline and Follow-Up Intervals

• eGFR and creatinine at baseline
• Recheck at month 3 and month 6 after starting
• Every 6 months if baseline eGFR is below 60 mL/min/1.73m2 (CKD stage 3 or worse)

A decline in eGFR of more than 15% from baseline over 6 months warrants dose review and nephrology consultation. Older men with CKD stage 3b or worse (eGFR <45 mL/min/1.73m2) should be considered for closer monitoring intervals of every 3 months [8].

Fluid Retention Warning Signs

Patients and caregivers should be instructed to report ankle swelling, rapid weight gain (more than 2 pounds in 24 hours or 5 pounds in one week), and dyspnea. These symptoms may indicate fluid retention driven by testosterone therapy and require urgent evaluation rather than watchful waiting.

Falls and Fracture Risk: An Underappreciated Monitoring Target

Testosterone and Muscle Mass in Older Men

Testosterone therapy modestly increases lean body mass and grip strength. The testosterone-alone arm of the Testosterone Trials (TTrials), which enrolled men aged 65 and older (N=790), showed a mean increase in lean mass of 1.6 kg at 12 months (pubmed.ncbi.nlm.nih.gov) [9]. Grip strength improved by approximately 1.6 kg-force, a change that may translate to reduced falls risk over the long term.

Short-Term Initiation Risks

The initiation phase carries competing risks. Dizziness from early erythrocytosis, orthostatic hypotension from rapid fluid shifts, and the sedating effects of any dose-related testosterone peak can all increase fall risk in the first 4 to 8 weeks. Checking orthostatic blood pressure and asking directly about dizziness at the week-4 visit can catch this before a fall occurs.

TUG Test as a Monitoring Tool

The Timed Up and Go test is a validated, 30-second functional screen recommended by the U.S. Preventive Services Task Force (uspstf.org) for falls risk in community-dwelling older adults [10]. A score above 12 seconds indicates elevated falls risk and should prompt referral to physical therapy regardless of testosterone therapy status. Document TUG results at baseline, month 6, and annually thereafter.

PSA and Prostate Monitoring

Frequency and Thresholds

• Baseline PSA before starting
• Recheck at month 3 and month 12
• Annually thereafter if PSA remains stable

The Endocrine Society guideline defines a PSA rise of more than 1.4 ng/mL from baseline over 12 months, or any single PSA above 4.0 ng/mL, as a threshold warranting urology referral and therapy reassessment [3]. Men with a baseline PSA between 3.0 and 4.0 ng/mL should have urology consultation before starting Jatenzo.

Why Older Men Warrant Particular Attention

The prevalence of subclinical prostate cancer rises steeply with age. Autopsy studies estimate that 30 to 40% of men in their 60s and more than 50% of men in their 80s have histologic prostate cancer that was never clinically diagnosed. Testosterone therapy does not appear to cause prostate cancer de novo based on current evidence reviewed by the Endocrine Society, but it may accelerate growth of pre-existing androgen-sensitive lesions [3]. That risk, while not definitively quantified, is reason for diligent PSA surveillance in men over 65.

Drug Interaction Monitoring in Polypharmacy Patients

Anticoagulants

Testosterone reduces the hepatic clearance of warfarin, raising the INR. A man stabilized on warfarin with a target INR of 2.0 to 3.0 may see his INR rise to 3.5 to 4.5 within 2 to 4 weeks of starting Jatenzo. INR should be checked 2 weeks after starting testosterone and after every dose change [4].

Insulin and Oral Hypoglycemics

Testosterone improves insulin sensitivity. Men with type 2 diabetes on sulfonylureas or insulin may experience hypoglycemia as testosterone therapy takes effect. Fasting glucose and HbA1c should be rechecked at month 3, with dose adjustment of hypoglycemic agents guided by home glucose logs [4].

Opioids

Chronic opioid use causes opioid-induced androgen deficiency, which is one reason some older men on long-term opioids are prescribed testosterone therapy. The interaction cuts both ways: testosterone may modestly attenuate opioid analgesia requirements, and dose changes in either direction require clinical reassessment of the other.

Deprescribing Considerations in Geriatric Patients

Not every older man who starts Jatenzo should remain on it indefinitely. Deprescribing is a legitimate clinical endpoint, not a failure.

When to Reassess Continuation

A structured reassessment at 6 months should ask three questions:

1. Has the patient's primary symptom burden (low energy, low libido, poor concentration) improved measurably?
2. Has serum testosterone reached the target range at the 3 to 5 hour window?
3. Has the patient experienced any dose-limiting adverse effects (hematocrit above 54%, systolic BP rise above 10 mmHg, eGFR decline above 15%)?

If the answer to question 1 is no AND the answer to question 2 is yes, testosterone therapy is biochemically effective but symptomatically insufficient. That pattern warrants reassessment of whether the patient's symptoms were truly androgen-driven, or whether another etiology (depression, sleep apnea, hypothyroidism) should be addressed.

Tapering and Discontinuation

Jatenzo does not require a prolonged taper because it produces no lasting suppression of the hypothalamic-pituitary-gonadal axis in men with primary hypogonadism. In men with secondary (hypogonadotropic) hypogonadism, stopping Jatenzo will return serum testosterone to pre-treatment levels within days because the oral formulation has no depot effect. Patients and caregivers should be counseled about symptom recurrence after discontinuation.

Monitoring Schedule Summary Table

| Timepoint | Serum T (3 to 5h) | Hematocrit | Blood Pressure | PSA | eGFR/Cr | TUG Test | INR (if on warfarin) | |---|---|---|---|---|---|---|---| | Baseline | Yes | Yes | Yes | Yes | Yes | Yes | Yes | | Week 2 | No | No | No | No | No | No | Yes | | Week 4 | Yes | Yes | Yes | No | No | Yes | Yes | | Month 3 | Yes | Yes | Yes | Yes | Yes | No | As needed | | Month 6 | Yes | Yes | Yes | No | Yes | Yes | As needed | | Month 12 | Yes | Yes | Yes | Yes | Yes | Yes | As needed | | Annually | Yes | Yes | Yes | Yes | Yes | Yes | As needed |